Estamos trabajando para incorporar este artículo al repositorio
Consulte el artículo en la página del editor
Consulte la política de Acceso Abierto del editor


The cytochrome P-450 (CYP) isoenzymes, a superfamily of heme proteins which are the terminal oxidases of the mixed function oxidases system, metabolize more than 70% of all clinically approved drugs. The highly polymorphic CYP2D6 isoform metabolizes more than 25% of most common drugs, and the phenotypes of the 70-plus allelic variants range from compromised to excessive enzymatic activity. Porphyrias are a group of inherited or acquired metabolic disorders of heme biosynthesis, due to a specific decrease in the activity of one of the enzymes of the heme pathway. Clinical signs and symptoms of porphyrias are frequently associated with exposure to precipitating agents, including clinically approved drugs. CYP enzymes, including CYP2D6, participate in the metabolism of some porphyrinogenic drugs, leading to the deregulation of heme biosynthesis. Considering that some of the drugs not recommended for use in porphyric patients are metabolized by CYP2D6, the presence of CYP2D6 polymorphisms in porphyric patients would influence the triggering of the disease when these individuals receive a precipitating agent that is metabolized by CYP2D6. To investigate CYP2D6 polymorphisms in porphyric patients, healthy Argentinean volunteers, porphyric patients, and a group of individuals with high levels of iron were studied. Results indicated that the CYP2D6*3 and CYP2D6*4 alleles, in particular, would be linked to the onset of disease. Predictive genotyping for CYP2D6 in porphyric patients holds promise as a method to improve the clinical efficacy of drug therapy and to personalize drug administration for these patients.


Documento: Artículo
Título:CYP2D6 polymorphisms in patients with porphyrias
Autor:Lavandera, J.V.; Parera, V.E.; Batlle, A.; Buzaleh, A.M.
Filiación:Centro de Investigaciones Sobre Porfirinas y Porfirias (CIPYP), CONICET, Hospital de Clínicas, Argentina
Department of Biological Chemistry, Facultad de Ciencias Exactas y Naturales, University of Buenos Aires, Argentina
Viamonte 1881 10 A, C1056ABA, Buenos Aires, Argentina
Palabras clave:cytochrome P450 2D6; hemoprotein; iron; isoenzyme; oxidoreductase; porphyrin derivative; adult; aged; allele; Argentina; article; clinical feature; controlled study; cytochrome P2D6 gene; disease association; DNA polymorphism; drug exposure; drug metabolism; enzyme activity; enzyme metabolism; enzyme regulation; female; gene; genetic analysis; genotype phenotype correlation; heme synthesis; human; iron blood level; major clinical study; male; metabolic disorder; porphyria; priority journal; protein family; protein function; Adolescent; Adult; Alleles; Child; Cytochrome P-450 CYP2D6; Female; Gene Frequency; Genotype; Humans; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Porphyrias
Página de inicio:259
Página de fin:263
Título revista:Molecular Medicine
Título revista abreviado:Mol. Med.
CAS:iron, 14093-02-8, 53858-86-9, 7439-89-6; oxidoreductase, 9035-73-8, 9035-82-9, 9037-80-3, 9055-15-6; Cytochrome P-450 CYP2D6, EC


  • Chang, G.W.M., Kam, P.C.A., The physiological and pharmacological roles of cytochrome P450 isoenzymes (1999) Anaesthesia, 54, pp. 42-50
  • Ingelman-Sundberg, M., The human genome project and novel aspects of cytochrome P450 research (2005) Toxicol. Appl. Pharmacol., 207, pp. 552-556
  • Burroughs, V.J., Maxey, R.W., Levy, R.A., Racial and ethnic differences in response to medicines: Toward individualized pharmaceutical treatment (2002) J. Natl. Med. Assoc., 94, pp. 1-26
  • Ingelman-Sundberg, M., Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity (2005) Pharmacogenomics J., 5, pp. 6-13
  • Scordo, M.A., Caputi, A.P., D'Arrigo, C., Fava, G., Spina, E., Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population (2004) Pharmacol. Res., 50, pp. 195-200
  • Ingelman-Sundberg, M., Pharmacogenetics of cytochrome P450 and its applications in drug therapy: The past, present and future (2004) Trends Pharmacol. Sci., 25, pp. 193-200
  • Saxena, R., Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with poor metabolizer phenotype (1994) Hum. Mol. Gen., 3, pp. 923-926
  • Sachse, C., Brockmoller, J., Bauer, S., Roots, I., Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences (1997) Am. J. Hum. Genet., 60, pp. 284-295
  • Van Der Weide, J., Steijns, L., Cytochrome P450 enzyme system: Genetic polymorphisms and impact on clinical pharmacology (1999) Ann. Clin. Biochem., 36, pp. 722-729
  • Batlle, A.M.D.C., Porfirinas y porfirias: Aspectos clínicos, bioquímicos y biología molecular. Serie: Actualizaciones Médico- Bioquímicas (1997) Acta Bioquím. Latinoamer., (SUPPL. 3), pp. 3-63
  • Nordmann, Y., Puy, H., Deybach, J.C., The porphyrias (1999) J. Hepatol., 30, pp. 12-16
  • Thadani, H., Deacon, A., Peters, T., Diagnosis and management of porphyria (2000) Br. Med. J., 320, pp. 1647-1651
  • Meyer, U.A., Schuurmans, M.M., Lindberg, R.L., A review of the pathogenesis of the neurological manifestations of the acute porphyrias (1998) Semin. Liver Dis., 18, pp. 43-52
  • Méndez, M., Rossetti, M.V., Batlle, A.M.D.C., Parera, V.E., The role of inherited and acquired factors in the development of porphyria cutanea tarda in the Argentinean population (2005) J. Am. Acad. Dermatol., 52, pp. 417-424
  • Daly, A.K., Steen, V.M., Fairbrother, K.S., Idle, J.R., CYP2D6 Multiallelism (1996) Methods in Enzymology: Cytochrome P450, 272, pp. 199-211. , Waterman MR, Johnson EF (eds.) Academic Press, chapter 22
  • Lennard, M.S., Genetic polymorphism of sparteine/debrisoquine oxidation: A reappraisal (1990) Pharmacol. Toxicol., 67, pp. 273-283
  • Bertilsson, L., Dahl, M.L., Dalen, P., Al-Shurbaji, A., Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs (2002) Br. J. Clin. Pharmacol., 53, pp. 111-122
  • Marez, D., Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution (1997) Pharmacogenetics, 7, pp. 193-202
  • Bradford, L.D., CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants (2002) Pharmacogenomics, 3, pp. 229-243
  • Meyer, U.A., Zanger, U.M., Molecular mechanisms of genetic polymorphisms of drug metabolism (1997) Annu. Rev. Pharmacol. Toxicol., 37, pp. 269-296
  • Cascorbi, I., Pharmacogenetics of cytochrome P4502D6: Genetic background and clinical implication (2003) Eur. J. Clin. Invest., 33, pp. 17-22
  • Caporaso, N., Landi, M.T., Vineis, P., Relevance of metabolic polymorphisms to human carcinogenesis: Evaluation of epidemiologic evidence (1991) Pharmacogenetics, 1, pp. 4-19
  • Agündez, J.A., Debrisoquin oxidation genotype and susceptibility to lung cancer (1994) Clin. Pharmacol. Ther., 55, pp. 10-14
  • Anwar, W.A., Abdel-Rahman, S.Z., El-Zein, R.A., Mostafa, H.M., Au, W.W., Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients (1996) Carcinogenesis, 17, pp. 1923-1929
  • Agündez, J.A., Ledesma, M.C., Benitez, J.M., Ladero, J.M., Rodriguez-Lescure, A., Diaz-Rubio, E., Diaz-Rubio, M., CYP2D6 genes and risk of liver cancer (1995) Lancet, 345, pp. 830-831
  • Wolf, C.R., Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility (1992) Carcinogenesis, 13, pp. 1035-1038
  • Anthony, L.B., Thomas, J.B., Hande, K.R., Cytochrome P-450IID6 phenotyping in cancer patients: Debrisoquine and dextromethorphan as probes (1995) Cancer Chemother. Pharmacol., 36, pp. 125-128
  • Topic, E., Stefanovic, M., Ivanisevic, A.M., Petrinovic, R., Curcic, I., The cytochrome P450 2D6 (CYP2D6) gene polymorphism among breast and head and neck cancer patients (2000) Clin. Chim. Acta, 296, pp. 101-109
  • Gardlo, K., Selimovic, D., Bolsen, K., Ruzicka, T., Abel, J., Fritsch, C., Cytochrome P4501A1 polymorphisms in a Caucasian population with porphyria (2003) Exp. Dermatol., 12, pp. 843-848
  • Christiansen, L., Bygum, A., Jensen, A., Thomsen, K., Brandrup, F., Horder, M., Petersen, N.E., Association between CYP1A2 polymorphism and susceptibility to porphyria cutanea tarda (2000) Hum. Genet., 107, pp. 612-614
  • Spear, B., Heath-Chiozzi, M., Huff, J., Clinical application of pharmacogenetics (2001) Trend Mol. Med., 7, pp. 201-204


---------- APA ----------
Lavandera, J.V., Parera, V.E., Batlle, A. & Buzaleh, A.M. (2006) . CYP2D6 polymorphisms in patients with porphyrias. Molecular Medicine, 12(9-10), 259-263.
---------- CHICAGO ----------
Lavandera, J.V., Parera, V.E., Batlle, A., Buzaleh, A.M. "CYP2D6 polymorphisms in patients with porphyrias" . Molecular Medicine 12, no. 9-10 (2006) : 259-263.
---------- MLA ----------
Lavandera, J.V., Parera, V.E., Batlle, A., Buzaleh, A.M. "CYP2D6 polymorphisms in patients with porphyrias" . Molecular Medicine, vol. 12, no. 9-10, 2006, pp. 259-263.
---------- VANCOUVER ----------
Lavandera, J.V., Parera, V.E., Batlle, A., Buzaleh, A.M. CYP2D6 polymorphisms in patients with porphyrias. Mol. Med. 2006;12(9-10):259-263.